Under the agreement, OriGen will send maternal blood samples to Premaitha's clinical laboratory in the UK, which will analyze them using the firm's Iona test.
The company's new clinical laboratory will provide interim and backup services for its customers.
This is My will offer the test at its clinics in Leeds, Manchester, Liverpool, Hull, Coventry, Halifax, Durham, and London.
The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.
Premaitha launched its CE-marked in vitro diagnostic Iona test for noninvasive prenatal aneuploidy screening earlier this year.
The partners will work to establish Centrum Badan as the preferred testing partner for the NGS-based test in Poland, which had 376,000 live births last year.
Under the three-year project award, Premaitha and St George's plan to establish a UK Centre of Excellence for Prenatal Screening.
Illumina and its subisidiary Verinata allege Premaitha's Iona test infringes two European patents relating to the use of cell-free fetal DNA for NIPT.
The companies are taking the CE-IVD route as opposed to the LDT model in the US due to Europe's distributed prenatal testing market and lower regulatory hurdles.
The next-generation sequencing-based test for chromosomal trisomies will be launched first in Europe, then in other territories recognizing the CE mark.
NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.
Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.
A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.
In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.